Ozzy Osbourne will come out of touring retirement and reunite with the full Black Sabbath lineup for the first time in 20 ...

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

Conductor Daniel Barenboim says he has been diagnosed with Parkinson’s disease. The 82-year-old issued a statement Thursday ...

Daniel Barenboim, the eminent conductor and pianist who stepped back from engagements in recent years citing health concerns, ...

The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced ...

The world-renowned Israeli-Argentine pianist and conductor Daniel Barenboim revealed Thursday he is suffering from ...

The maestro has appeared more frail since 2022, canceling scheduled performances that included a new production of Wagner's ...

The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' drug-device combination to treat ...

The U.S. Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only ...

“He’s very happy to be coming back and very emotional about this," Sharon told The Sun. “Parkinson’s is a progressive disease ...

The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease seve ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...